Skip to ContentSkip to Navigation
About us Practical matters How to find us prof. dr. E. (Edwin) Bremer

Publications

Antibody desolvation with sodium chloride and acetonitrile generates bioactive protein nanoparticles

Direct Functionalization of Polysaccharide-Based Xylan Phenyl Carbonate Nanoparticles with Tumor Cell Specific Antibodies

Novel high-yield potato protease inhibitor panels block a wide array of proteases involved in viral infection and crucial tissue damage

VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses

A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells

Galectin-9 has non-apoptotic cytotoxic activity toward acute myeloid leukemia independent of cytarabine resistance

Notch1 promotes resistance to cisplatin by up-regulating Ecto-5'-nucleotidase (CD73) in triple-negative breast cancer cells

Salivary extracellular miRNAs for early detection and prognostication of esophageal cancer: a clinical study

Read more

Press/media

Groningse CAR-T-celtherapie krijgt KWF-subsidie

2,6 miljoen subsidie voor revolutionair oncologie onderzoek

Miljoenensubsidie voor UMCG-onderzoek naar therapie voor uitbehandelde kankerpatiënten

UMCG ontvangt grote EU-subsidie voor onderzoek naar nieuwe immuuntherapie bij kanker

Grote EU-subsidie voor UMCG voor onderzoek naar CAR-T immuuntherapie bij kanker

Ruim 5 miljoen voor uniek Nederlands platform voor gen- en celtherapie

Ruim 5 miljoen voor cel- en gentherapie

i-direct

Read more